UNSPSC 51151526: Zanapezil

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C25H32N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A0800O89N, chemically known as 1-propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)- but generally known as zanapezil, which bears US NIH Compound Identifier 198752. The term ZANAPEZIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47).

Most nations schedule zanapezil under HS 29333999 and SITC 51574. As of Q4 2014, ZANAPEZIL remains the US FDA Preferred Term for this commodity. Zanapezil bears US NLM identifiers UMLS ID C1883595 and NCI Concept Code C66683. SMILES: C1CCNC2=C(C1)C=CC(=C2)C(=O)CCC3CCN(CC3)CC4=CC=CC=C4.

UNSPSC 51151526 Zanapezil is a Commodity code tracking pharmaceutical products, specifically opioid antagonists and related emergency-response medications. State and local governments procure under this code primarily for community health and overdose-prevention initiatives, though recent activity shows significant scope mismatch — the two recent opportunities posted under this code involve naloxone (an opioid antagonist distinct from zanapezil) and direct-to-manufacturer prescription programs rather than zanapezil specifically. Issuing bodies include county health departments and state health and human services commissions pursuing both supply contracts and vendor-capability assessments for pharmacy benefit programs.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year term with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: the due date in the source predates the posting date, indicating a data inconsistency). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured employer and health-plan contracting outside traditional pharmacy benefit manager and group purchasing organization arrangements. The code shows limited recent activity, and the opportunities posted do not consistently align with zanapezil procurement — the Seminole County solicitation targets naloxone and deactivation systems for community health delivery, while the Texas RFI explores broader pharmacy benefit restructuring without zanapezil-specific specifications.